# A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above

> **NCT07204964** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 971 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** Flu mRNA (Formulation B1)
- **BIOLOGICAL:** Flu mRNA (Formulation B3)
- **BIOLOGICAL:** Flu mRNA(Formulation A)
- **COMBINATION_PRODUCT:** Comparator 1
- **COMBINATION_PRODUCT:** Comparator 2
- **COMBINATION_PRODUCT:** Comparator 3

## Key facts

- **NCT ID:** NCT07204964
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-10-07
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 971 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07204964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07204964, "A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07204964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*